Abstract
Treatment of diabetes mellitus type 2 (T2DM) is a serious challenge which forces to search for new approaches in order to improve the results of pharmacotherapy. Recent advances in diabetology pertain to incretin-directed therapies. Along with traditional defects (insulin resistance, β-cell dysfunction), a significant contribution to the development and progression of the disease is made by a reduction of "incretin effect" (Fig. 1). The concept of reduced "incretin effect" served as the basis for the development and introduction into clinical practice of the innovative medications the action of which is based on the "incretin effect" - glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). [12, 17].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
